A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS
Status:
Completed
Trial end date:
2009-10-31
Target enrollment:
Participant gender:
Summary
To establish a pharmacokinetic (PK) profile of BG00012, as measured by its primary
metabolite, monomethyl fumarate (MMF), during a 24-hour dosing period in subjects with
relapsing-remitting multiple sclerosis (RRMS), with a variety of baseline demographic
characteristics.